Deborah York, NP
Psychiatric/Mental Health · Denver, CONPI 1952823403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,042 of the $158,004 with a category attached, or 69.0%. 10 manufacturers reported payments, led by Vanda Pharmaceuticals Inc. at 49.0% of the total. Reporting peaked in 2024 at $69,047 and has fallen 84.8% since, to $10,489 in 2025. Among psychiatric/mental health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $434.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$77K
- Alkermes, Inc.$37K
- AbbVie$31K
- Boehringer Ingelheim$7K
- Neurocrine Biosciences, Inc.$4K
- Sunovion Pharmaceuticals Inc.$848
- plus $1K from 4 others
Across 76 payments — averaging $7910.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$301K
- Vanda Pharmaceuticals Inc.$163K
- Alkermes, Inc.$105K
- Boehringer Ingelheim Pharma GmbH & Co.kg$32K
What the payments were for
- Consulting fees$5,0003%
- Speaking & faculty fees$109,04269%
- Travel & lodging$34,65722%
- Food & beverage$9,3056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 138 | $77,468 |
| Alkermes, Inc. | 89 | $36,646 |
| AbbVie(2 entities) | 96 | $30,620 |
| Boehringer Ingelheim | 13 | $7,395 |
| Neurocrine Biosciences, Inc. | 5 | $3,552 |
| Sunovion Pharmaceuticals Inc. | 7 | $848 |
| Eli Lilly | 3 | $578 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $487 |
| Biogen | 4 | $356 |
| Axsome Therapeutics, Inc. | 2 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$158,004 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 39 | $957 |
| ProgesteroneProgesterone, Micronized | 22 | $946 |
| Clonazepam | 22 | $362 |
| Lamotrigine | 21 | $323 |
| Estradiol | 24 | $249 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $194 |
| Trazodone Hcl | 12 | $142 |
| Diazepam | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Denver
- Audrey StrockDenver$499K
- Ivy HooDenver$8K
- Mary EvansDenver$7K
- Kristina MordecaiDenver$6K
- Brandon BurelleDenver$5K
- Margeaux KingDenver$5K
- Nataliya HayesDenver$4K
- Laira CowperDenver$4K
- Mykol WarnerDenver$4K
- Chelsie MonroeLittleton$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.